Background. Endothelin is an endothelium-derived peptide that produces sustained contraction of arterial and venous smooth muscle in vitro. Several studies have established endothelin as a systemic, renal, and coronary vasoconstrictor in vivo at pharmacological concentrations. Such concentrations of endothelin were antinatriuretic in association with activation of the renin-angiotensin-aldosterone system. Recent studies have demonstrated that endothelin is present in the plasma and that its plasma concentrations are increased in various pathological states associated with systemic and renal vasoconstriction. To date, it remains unclear if such increases in circulating endothelin are associated with biological activity. Thus, the objective of this study was to determine the biological action of endothelin on cardiorenal and endocrine function through administration of exogenous endothelin, which achieves plasma concentrations that have been reported in various pathophysiological conditions. Methods and Results. Experiments were conducted in two groups of anesthetized dogs. In group 1, endothelin-1 was infused intravenously at 2.5 ng/kg/ml (n=6), which produced a doubling of circulating concentrations. Group 2 (n =8) received saline vehicle to serve as a time control. The current studies demonstrate that a twofold increase in plasma endothelin concentrations did not affect mean blood pressure or coronary blood flow. Heart rate and cardiac output decreased in association with increased renal and systemic vascular resistances and antinatriuresis.
Conclusions. The present studies demonstrate that endothelin at pathophysiological plasma concentrations produced by exogenous endothelin has biological action. These studies support a functional role for endogenous endothelin as a potentially pathophysiological vasoconstrictor peptide hormone in the regulation of cardiovascular, renal, and endocrine function. (Circulation 1991;83:1808-1814) E ndothelin (ET) is an endothelium-derived peptide that produces sustained contraction of arterial and venous vascular smooth muscle in vitro.12 Recent in vivo studies3-5 have demonstrated that at pharmacological concentrations ET is also a potent coronary, renal, and systemic vasoconstrictor, which may decrease sodium excretion and activate the renin-angiotensin-aldosterone system. These actions are consistent with a role for ET as an important cardiovascular regulatory peptide.
Increasing evidence indicates that, in addition to its known role as an autacoid, ET is present in the plasma of normal humans and animals.67 The importance of its presence in the circulation is underscored by increased plasma levels of ET in disorders of cardiovascular and renal dysfunction. Specifically, plasma ET concentrations have been reported to be increased threefold in congestive heart failure, twofold in essential hypertension, threefold in cardiogenic shock, and twofold in transplantation-associated hypertension. [8] [9] [10] [11] [12] Blood flows and arterial blood pressures were recorded on a strip recorder (model 2200, Gould, Cleveland, Ohio).
Experimental Protocol Synthetic endothelin administration. After an equilibration period of 1 hour after completion of surgical procedures, and during which inulin and saline infusions at 1 ml/min were started, two consecutive 20-minute baseline control clearances were performed. At the midpoint of each clearance period, hemodynamic parameters were measured, and arterial blood was collected for subsequent measurement of plasma atrial natriuretic factor (ANF), plasma renin activity, ET, aldosterone, and chemistries (inulin, lithium, and sodium). Urine was collected during the entire 20-minute clearance period for measurement of electrolytes.
After completion of these baseline clearances, ET-1 (Peninsula Laboratories, Inc., Belmont, Calif.) was infused intravenously at 1 ml/min in dogs in the experimental group 1 (n=6) at 2.5 ng/kg/min. This dose was chosen to double circulating ET based on pilot studies. Group 2 (n=8) received saline vehicle at 1 ml/min. After a lead-in period of 30 minutes, three 20-minute clearances were obtained, with measurements and collections as described above for the control periods. The total time of ET infusion was 90 minutes.
When the ET infusion was completed, two 60-minute recovery periods were observed during which no peptide was infused. A 20-minute recovery clearance was obtained at the end of each recovery period; these values were averaged.
The biological activity of the ET used in these experiments was tested using a bioassay in WistarKyoto rats. Each lot number of ET supplied was verified as biologically active if a bolus of 1 ,ug into the anesthetized rat produced a rapid hypertensive response.
Collection ofsamples. Blood for plasma chemistries was placed in heparinized tubes, packed in ice, centrifuged at 2,500 rpm, and refrigerated along with urine chemistry samples pending analysis. Blood for hormone assays was placed in EDTA tubes on ice, and after centrifugation at 2,500 rpm, plasma was decanted and stored at -20°C until analysis. Plasma ANF was measured by radioimmunoassay to human ANF-(99-126) as previously described.13 Plasma renin activity was determined by radioimmunoassay using the method of Haber et al.14 Aldosterone levels were measured after dichloromethane extraction by radioimmunoassay (immuno-aldocolesone-iodine-125 kit D18, Pantex, Santa Monica, Calif.).
Plasma ET was determined by the ET-1,2[1251] assay system (Amersham International, Amersham, UK). Blood was drawn from dogs into tubes containing chilled potassium EDTA and immediately placed on ice until being centrifuged at 4°C. Plasma was separated and frozen at -20°C until assay. Before the radioimmunoassay, plasma was acidified with 0.5% trifluoroacetic acid. C8 Bond Elut cartridges (Analytichem International, Harbor City, Calif.)
were washed with 4 ml methanol and 4 ml water to (Figure 1) , an immediate and significant increase in systemic vascular resistance and a decrease in both heart rate and cardiac output were observed; these responses persisted through the recovery period. These responses were also significant when compared with the saline time control group (Figure 2 Pathophysiological concentrations of ET affected systemic hemodynamics, producing a significant increase in systemic vascular resistance and a decrease in cardiac output (Figure 2 ). Such actions have been observed in previous studies, using pharmacological and pressor doses of ET.3,4 In such previous investigations, the pressor response to exogenous ET was associated with a progressive bradycardic response.418,19 In the present study, much lower concentrations of plasma ET were also associated with progressive bradycardia. Since this decrease in heart rate was not accompanied by changes in mean arterial pressure, ET may have a direct effect on the cardiac conduction system, as suggested by Yamasaki et al, 20 or it may serve as a neuromodulator21,22 to alter chronotropic activity.
However, we cannot rule out the possibility that the bradycardia observed in this study was a baroreflexmediated mechanism to maintain constant mean arterial pressure. Despite the negative chronotropic action of ET in the current study, coronary blood flow and *t Consistent with the preferential renal vasoconstrictor action of ET at pharmacological concentrations, exogenous ET caused significant reductions in renal blood flow and increases in renal vascular resistance at the doses used in the present study ( Figure 3) . The effect on glomerular filtration rate was more complex, characterized by a reversible decrease in glomerular filtration rate. At pathophysiological concentrations, the glomerular filtration rate decreased only during the first clearance. The effect of these plasma concentrations on glomerular filtration rate can only be speculated. Because infusions of higher pharmacological concentrations of ET typically result in a progressive decrease in glomerular filtration rate,23,24 the observations of the present studies suggest that ET may have varying threshold actions on both the afferent and efferent arterioles.25 Its interaction with endogenous vasodilators, such as ANF and endothelium-derived relaxing factor, at these sites may also regulate local vascular tone.
Despite the renal vasoconstrictor action, no significant changes in sodium excretion were observed in the group that received exogenous ET. However, the twofold increase in plasma ET concentrations did prevent the modest natriuresis that was observed in the vehicle group, suggesting that pathophysiological concentrations of ET may evoke the onset of a decrease in sodium excretion as demonstrated with more pharmacological concentrations. Since wholekidney delivery of sodium from the proximal tubule did not change significantly, as determined by the fractional excretion of lithium, this antinatriuretic effect may be secondary to enhanced tubular reabsorption of sodium beyond the proximal tubule. Such a distal tubular action of ET has been suggested in preliminary studies that demonstrate possible uptake or production of ET by distal tubular cells. 26 Baseline plasma ET concentrations in the anesthetized dogs in the current study were higher than concentrations reported in previous studies. This may 
